ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Artesunate

Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.

Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.

Drug pageArtesunate: every studyMany companies study it; this page follows only the 17 they lead. All 115 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 8, 200717 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only60 open or runningphase 4since Mar 8, 2007Apr 18, 2006none ahead
Frantz Viral Therapeutics44 open or runningphase 2since Sep 19, 2019Sep 19, 2019Dec 2026phase 2 · NCT06075264
Metanoic Healthits history only22 open or runningphase 2since Jul 7, 2025Jul 7, 2025Jun 30, 2027phase 2 · NCT07095478
Shin Poong Pharmaceuticalits history only20 open or runningphase 2since Sep 13, 2018Sep 13, 2018none ahead
Amivasits history only11 open or runningphase 2since Feb 25, 2025Feb 25, 2025May 31, 2028phase 2 · NCT06853184
Pfizerits history only10 open or runningphase 1since May 4, 2009May 4, 2009none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 4since Sep 10, 2009Sep 10, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Frantz Viral Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2019First study: phase 2 study in Papillomavirus InfectionsFirst studyNCT04098744 · 78 planned · United States
  2. Sep 22, 2022Phase 2 study in Papillomavirus InfectionsNCT05555862 · 17 enrolled · United States
  3. Oct 4, 2023Phase 2 study in Vulvar DiseasesNCT06075264 · 27 planned · United States
  4. Jan 3, 2024Phase 2 study in Anal High-grade Squamous Intraepithelial LesionNCT06206564 · 48 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Vulvar DiseasesNCT06075264
  2. Dec 28, 2026Primary completion: phase 2 study in Papillomavirus InfectionsNCT05555862
  3. Dec 31, 2026Primary completion: phase 2 study in Anal High-grade Squamous Intraepithelial LesionNCT06206564

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Frantz Viral Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06206564Anal High-grade Squamous Intraepithelial Lesion · United States2RecruitingDec 31, 202648
NCT06075264Vulvar Diseases · United States2RecruitingDec 202627
NCT05555862Papillomavirus Infections · United States2Active, not recruitingDec 28, 202617
NCT04098744Papillomavirus Infections · United States2RecruitingJul 31, 202678

How it is read

Names in the registry

  • “Artesunate”, 6 entries
  • “Artesunate + Amodiaquine”, 3 entries
  • “Artesunate ointment”, 2 entries
  • “Artesunate vaginal insert”, 1 entry
  • “Artesunate-amodiaquine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.